Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01890837
Recruitment Status : Completed
First Posted : July 2, 2013
Last Update Posted : June 13, 2016
Cato Research
Information provided by (Responsible Party):
Tsumura USA

Brief Summary:
The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Abdominal Pain Drug: Daikenchuto (TU-100) Drug: Placebo Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome
Study Start Date : August 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Arm Intervention/treatment
Experimental: Daikenchuto (TU-100) 15g/day
Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
Drug: Daikenchuto (TU-100)
Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

Placebo Comparator: Placebo
Placebo TID
Drug: Placebo
Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.

Primary Outcome Measures :
  1. Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS [ Time Frame: 14 days ]
  2. Sensation threshold for pain in response to distention of the rectum [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Rectal compliance at half-maximum pressure (Pr1/2) [ Time Frame: 14 days ]
  2. Rectal sensation thresholds (gas, urgency to defecate, first sensation) [ Time Frame: 14 days ]
  3. Rectal sensation ratings (pain, gas) in response to 32 mmHg distension of the rectum [ Time Frame: 14 days ]
  4. Rectal tone response to feeding 1,000 kcal meal [ Time Frame: 14 days ]
  5. Stool frequency [ Time Frame: 21 days ]
  6. Stool consistency as measured by the Bristol stool scale [ Time Frame: 21 days ]
  7. Daily average severity of abdominal pain on 100mm VAS [ Time Frame: 21 days ]
  8. Worst severity of abdominal pain each day measured on 100mm VAS scale [ Time Frame: 21 days ]
  9. Daily average severity of bloating on 100mm VAS scale [ Time Frame: 21 days ]
  10. IBS-QOL (Quality of Life) score [ Time Frame: 14 days ]
  11. Ease of bowel movements [ Time Frame: 21 days ]
  12. Completeness of evacuation [ Time Frame: 21 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Meet Rome III criteria for IBS.
  2. Willing and able to provide written informed consent.
  3. If a female of childbearing potential, must be using an acceptable form of contraception during the study and for 30 days after the last dose. Acceptable methods include surgical sterilization, hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing), condoms used with a spermicide, an IUD [Intrauterine device] or abstinence.

    Females are not considered to be of childbearing potential if they are postmenopausal for at least 2 years or have been surgically sterilized.

  4. Aged 18 to 65 years, inclusive.
  5. Have a body mass index (BMI) between 18 and 40 kg/m2, inclusive.
  6. Have a negative urine drug screening at Visit 1.
  7. Have normal or not clinically significant laboratory results as reviewed by the study physicians.
  8. Have a normal rectal examination result on file within the past 2 years or performed at Visit 1 in order to exclude the possibility of an evacuation disorder (examination must exclude findings suggestive of an evacuation disorder such as high sphincter tone at rest, failure of perineal descent and spasm, tenderness or paradoxical contraction of the puborectalis muscles).
  9. Agree to avoid alcohol during the entire study to avoid corrupting the data from the rectal barostat tests.

Exclusion Criteria:

  1. Have a structural or metabolic diseases or conditions that affect the GI system.
  2. Be taking any medication that in the opinion of the principal investigator has a potential to alter GI transit (this includes but is not limited to osmotic or stimulant laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, gabapentin, pregabalin, narcotics, anticholinergics, antidepressants [including selective norepinephrine reuptake inhibitors], antipsychotics, opiates, GABAergic agents and benzodiazepines).

    Note: Tricyclic antidepressants are permissible at doses equal to or less than 25 mg daily; selective serotonin reuptake inhibitor antidepressants are permissible at low, stable doses. Analgesics such as Tylenol, ibuprofen, naproxen and aspirin are not permissible during Visits 2 and 3 to avoid corrupting data from the rectal barostat tests. All medications will be reviewed by the principal investigator on a case by case basis.

    Rescue medications: Rescue medications will be reviewed and approved as necessary for exacerbation of constipation or diarrhea since the study medication treatment period is about 14 days total. The patient will contact the study staff to request review and approval of the use of a rescue medication by the principal investigator. The use of the rescue medication will be documented by the patient in the bowel pattern, bloating and pain diary. Rescue medications are not allowed within 7 days of the rectal sensation studies to ensure data integrity.

  3. Have clinical evidence, including but not limited to, of a clinically significant abnormal physical examination or laboratory value or of a past event documented in the past medical record, or current clinically significant abnormal physical examination or laboratory value that could indicate significant cardiovascular, respiratory, renal, hepatic, GI, hematological, neurological, psychiatric or other diseases that interfere with the objectives of the study. If a laboratory test value falls outside of the reference range and is considered clinically significant, it may be repeated once at the discretion of the principal investigator. If the laboratory test result remains abnormal and clinically significant, the patient will be discontinued from the study and referred to a primary care physician for evaluation.
  4. Be a known substance abuser or be considered to be an alcoholic not in remission.
  5. Have participated in another clinical study in the past 30 days.
  6. Have a history of allergic reactions to egg, ginseng, ginger or Sichuan pepper.
  7. Be clinically lactose intolerant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01890837

United States, Minnesota
Mayo Clinic, Rochester Methodist CRU
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Tsumura USA
Cato Research
Principal Investigator: Michael Camilleri, MD Mayo Clinic

Responsible Party: Tsumura USA Identifier: NCT01890837     History of Changes
Other Study ID Numbers: TU100CPT5
First Posted: July 2, 2013    Key Record Dates
Last Update Posted: June 13, 2016
Last Verified: June 2016

Keywords provided by Tsumura USA:
Rectal Compliance
Rectal Sensation
Rectal Tone

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Abdominal Pain
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive